Page last updated: 2024-11-05

actinium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Actinium (Ac) is a radioactive, silvery-white metal that is a member of the actinide series. It is found in trace amounts in uranium ores. Actinium is a highly radioactive element, with a half-life of 21.77 years. It emits alpha, beta, and gamma radiation. Actinium is not found naturally in significant quantities and is primarily produced artificially by bombarding radium with neutrons. Actinium is used in research and medicine. It is used as a source of neutrons and as a tracer in biological studies. Actinium is also being investigated as a potential treatment for cancer. It is studied for its radioactive properties and potential applications in various fields, including nuclear energy and medicine. Due to its radioactive nature and limited availability, actinium has no significant commercial uses.'

Actinium: A trivalent radioactive element and the prototypical member of the actinide family. It has the atomic symbol Ac, and atomic number 89. Its principal isotope is 227 and it decays primarily by beta-emission. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23965
CHEBI ID33337
MeSH IDM0000279

Synonyms (11)

Synonym
actinium
actinium atom
CHEBI:33337
89ac
aktinium
7440-34-8
actinio
ac
DTXSID10225388
DB12860
Q27115612

Research Excerpts

Overview

Actinium-225-DOTATATE is a form of targeted alpha therapy (TAT) that results in more efficient tumor cell killing owing to the substantially higher linear energy transfer of alpha particles. It decays with a 10-day half-life and generates three alpha-particle-emitting daughters.

ExcerptReferenceRelevance
"Actinium-225 is a highly radiotoxic alpha-emitting radionuclide, which is currently in the spotlight owing to its promising radiotherapeutic applications in nuclear medicine. "( Solid-phase extraction of
Carbonez, P; Cusnir, R; Froidevaux, P; Straub, M, 2022
)
2.16
"Actinium-225-DOTATATE is a form of targeted alpha therapy (TAT) that results in more efficient tumor cell killing owing to the substantially higher linear energy transfer of alpha particles."( Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment: Actinium-225-DOTATATE and Combined Therapies.
Bal, C; Chandekar, KR; Satapathy, S, 2023
)
1.88
"Actinium-225 is an alpha-emitting radionuclide that is highly encouraging as a therapeutic approach and more promising for targeted alpha therapy (TAT)."( A review of recent advancements in Actinium-225 labeled compounds and biomolecules for therapeutic purposes.
Bokhari, TH; Hassan, M; Khosa, MK; Lodhi, NA; Usman, M, 2023
)
1.91
"Actinium-225 is a promising isotope for targeted-α therapy. "( Spectroscopic and computational investigation of actinium coordination chemistry.
Batista, ER; Berg, JM; Birnbaum, ER; Cross, JN; Engle, JW; Ferrier, MG; Kozimor, SA; La Pierre, HS; Lezama Pacheco, JS; Stein, BW; Stieber, SC; Wilson, JJ, 2016
)
2.13
"Actinium-225 (225 Ac) is an alpha particle-emitting radionuclide that generates 4 net alpha particle isotopes in a short decay chain to stable 209 Bi, and as such can be described as an alpha particle nanogenerator."( Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.
McDevitt, MR; Miederer, M; Scheinberg, DA, 2008
)
1.35
"Actinium-225 is a potential generator for alpha-particle therapy: it decays with a 10-day half-life and generates three alpha-particle-emitting daughters."( Enhanced retention of the alpha-particle-emitting daughters of Actinium-225 by liposome carriers.
Jaggi, JS; Kappel, BJ; McDevitt, MR; Scheinberg, DA; Sgouros, G; Sofou, S,
)
1.09

Effects

Actinium-225 (225Ac) has been developed into potent targeting drug constructs and is in clinical use against acute myelogenous leukemia. It generates a total of four alpha-particles per parent decay rendering it an attractive candidate for alpha therapy.

ExcerptReferenceRelevance
"Actinium-225 has a 10-day half-life and generates a total of four alpha-particles per parent decay rendering (225)Ac an attractive candidate for alpha-therapy."( Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases.
Chang, MY; Seideman, J; Sofou, S, 2008
)
1.07
"Actinium-225 (225Ac) has emerged as a promising therapeutic radioisotope for targeted alpha therapy. "( Challenges and opportunities in developing Actinium-225 radiopharmaceuticals.
Dhiman, D; Sood, A; Vatsa, R, 2022
)
2.43
"Actinium- 225 has been developed into potent targeting drug constructs and is in clinical use against acute myelogenous leukemia."( Actinium-225 in targeted alpha-particle therapeutic applications.
McDevitt, MR; Scheinberg, DA, 2011
)
2.53
"Actinium-225 has a 10-day half-life and generates a total of four alpha-particles per parent decay rendering (225)Ac an attractive candidate for alpha-therapy."( Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases.
Chang, MY; Seideman, J; Sofou, S, 2008
)
1.07

Toxicity

ExcerptReferenceRelevance
" Therefore, a dose level of at least 28 kBq/kg may be a safe starting dose in humans."( Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
Cheung, NK; Kramer, K; McDevitt, MR; Miederer, M; Scheinberg, DA; Sgouros, G, 2004
)
0.32
" However, dry mouth is a common side effect that caused about a quarter of patients to stop therapy."( Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Beheshti, A; Bruchertseifer, F; D'Alessandria, C; Eiber, M; Feuerecker, B; Gafita, A; Gschwend, JE; Heck, M; Knorr, K; Kratochwil, C; Morgenstern, A; Pickhard, A; Retz, M; Seidl, C; Tauber, R; Weber, WA, 2021
)
0.91
" Xerostomia and myelosuppression are common early treatment-emergent adverse events in patients receiving this therapy; however, data on long-term toxicity are relatively scarce."( Delayed Nephrotoxicity After 225Ac-PSMA-617 Radioligand Therapy.
Gill, HJS; Maheshwari, P; Satapathy, S; Sharma, A; Sood, A, 2022
)
0.72
"Ac-PSMA RLT is a safe and potentially effective treatment option for patients with mCRPC."( Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis.
Agrawal, K; Bishnoi, K; Panda, RA; Parida, GK, 2023
)
1.22

Dosage Studied

ExcerptRelevanceReference
" No immune response occurred when a homologous carrier was used or when a heterologous carrier was applied at a dosage of 10 microg per immunization via intravenous injection."( Conjugation, immunoreactivity, and immunogenicity of calix[4]arenes; model study to potential calix[4]arene-based Ac3+ chelators.
Bos, ES; de Haan, AS; Grote Gansey, MH; Reinhoudt, DN; Verboom, W,
)
0.13
" Therapy was examined with native trastuzumab and 220, 330, and 450 nCi of (225)Ac-labeled trastuzumab or (225)Ac-labeled control antibody at different dosing schedules."( Targeted actinium-225 in vivo generators for therapy of ovarian cancer.
Borchardt, PE; McDevitt, MR; Miederer, M; Scheinberg, DA; Yuan, RR, 2003
)
0.74
" In the cumulative dosing schedule, single doses of approximately 37 kBq/kg resulted in no toxicity at 6 wk."( Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
Cheung, NK; Kramer, K; McDevitt, MR; Miederer, M; Scheinberg, DA; Sgouros, G, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
scandium group element atom
actinoid atom
f-block element atom
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (231)

TimeframeStudies, This Drug (%)All Drugs %
pre-199037 (16.02)18.7374
1990's13 (5.63)18.2507
2000's38 (16.45)29.6817
2010's75 (32.47)24.3611
2020's68 (29.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 78.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index78.95 (24.57)
Research Supply Index5.49 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index136.89 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (78.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.42%)5.53%
Reviews32 (13.33%)6.00%
Case Studies10 (4.17%)4.05%
Observational0 (0.00%)0.25%
Other197 (82.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]